Document Detail


Cardiac Structure and Function and Prognosis in Heart Failure With Preserved Ejection Fraction: Findings From the Echocardiographic Study of the Treatment Of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial.
MedLine Citation:
PMID:  25122186     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: -Abnormalities in cardiac structure and function in heart failure with preserved ejection fraction (HFpEF) may help identify patients at particularly high risk for cardiovascular morbidity and mortality.
METHODS AND RESULTS: -Cardiac structure and function were assessed by echocardiography in a blinded core laboratory at baseline in 935 patients with HFpEF (left ventricular ejection fraction [LVEF] ≥45%) enrolled in the Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial and related to the primary composite outcome of cardiovascular (CV) death, HF hospitalization, or aborted cardiac arrest, and its components. At a median follow-up of 2.9 years, 244 patients experienced the primary outcome. LV hypertrophy (LVH; adjusted HR 1.52, 95% CI 1.16-2.00), elevated LV filling pressure (E/E'; adjusted HR 1.05 per 1 integer increase; 95% CI 1.02-1.07), and higher pulmonary artery pressure assessed by the tricuspid regurgitation (TR) velocity (HR 1.23 per 0.5 m/sec increase; 95% CI 1.02-1.49) were associated with the composite outcome and HF hospitalization alone after adjusting for clinical and laboratory variables. The risk of adverse outcome associated with LVH was additive to the risk associated with elevated E/E'.
CONCLUSIONS: -Among HFpEF patients enrolled in TOPCAT, LVH, higher LV filling pressure, and higher pulmonary artery pressure were predictive of HF hospitalization, CV death, or aborted cardiac arrest independent of clinical and laboratory predictors. These features, both alone and in combination, identify HFpEF patients at particularly high risk for CV morbidity and mortality. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier NCT00094302.
Authors:
Amil M Shah; Brian Claggett; Nancy K Sweitzer; Sanjiv J Shah; Inder S Anand; Eileen O'Meara; Akshay S Desai; John F Heitner; Guichu Li; James Fang; Jean Rouleau; Michael R Zile; Valetin Markov; Vyacheslav Ryabov; Gilmar Reis; Susan F Assmann; Sonja M McKinlay; Bertram Pitt; Marc A Pfeffer; Scott D Solomon
Related Documents :
9935276 - A risk-benefit assessment of abciximab in angioplasty.
12872946 - Kinematic and deformation analysis of 4-d coronary arterial trees reconstructed from ci...
25088106 - Cardiac sympathetic hyperactivity in chronic kidney disease - a comparison between haem...
24204736 - Plasma high sensitivity troponin t levels in adult survivors of childhood leukaemias: d...
3128906 - Feline aortic thromboemboli and the potential utility of thrombolytic therapy with tiss...
18649956 - Autonomic nervous system instability, tetanic necrosis of the heart and myocardial tnfa...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-8-13
Journal Detail:
Title:  Circulation. Heart failure     Volume:  -     ISSN:  1941-3297     ISO Abbreviation:  Circ Heart Fail     Publication Date:  2014 Aug 
Date Detail:
Created Date:  2014-8-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101479941     Medline TA:  Circ Heart Fail     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A nationwide study of SLE in Japanese identified subgroups of patients with clear signs patterns and...
Next Document:  All of the above: When multiple correct response options enhance the testing effect.